Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The safety and efficacy of Isa-VRd in patients with transplant-ineligible NDMM

In this video, Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, shares updates from a study evaluating the safety and efficacy of isatuximab in combination with bortezomib, lenalidomide and dexamethasone (Isa-VRd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). This regimen was well tolerated, with almost all patients achieving a very good partial response (VGPR), and Dr Ocio further highlights the toxicity profile of this regimen. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.